• January 5, 2016Chairman’s Annual Update
 
Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 04 Jan 2016

    Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
    Read More

     

  • 23 Dec 2015

    Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens
    Read More

     

  • 01 Dec 2015

    Agenus to Present at the Oppenheimer 26th Annual Healthcare Conference
    Read More

     

  • 12 Nov 2015

    Agenus R&D Update to Be Held on November 19, 2015
    Read More

     

  • 05 Nov 2015

    Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions
    Read More

     

  • 27 Oct 2015

    Agenus Reports Third Quarter 2015 Financial Results
    Read More